Official UK procurement notice
HUTH/23/003 PromethION DNA / RNA Gene Sequencing Machine
Authority: Hull University Teaching Hospitals NHS Trust (Central government)
What is being bought
Published requirement descriptionThis notice is being published to inform of an award of a contract to Oxford Nanopore Technologies for a PromethION DRA / RNA Gene Sequencer.
CPV: Biomedical equipment · Research laboratory services
The lotProcurement structure
single lot · no lot value publishedLot #1The Trust has been awarded external UKRI funding to purchase an Oxford Nanopore…
The Trust has been awarded external UKRI funding to purchase an Oxford Nanopore Technologies (ONT) Promethion 24 sequencing device. This is to support several defined long-read sequencing projects, and wider research objectives. A condition of the funding is that this must be delivered by the end of March 2023.
Procedure terms & legal framework
From the official record- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 11 Jan 2023, 15:58 GMT
- Last source update
- 11 Jan 2023, 15:58 GMT
- Authority reference
DN649792- FTS notice number
2023/S 000-000859- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-0396afFind a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
The Trust has been awarded external UKRI funding to purchase an Oxford Nanopore Technologies (ONT) Promethion 24 sequencing device. This is to support several defined long-read sequencing projects, and wider research objectives. A condition of the funding is that this must be delivered by the end of March 2023.
Metagenomics is a rapidly emerging field, evaluating the composition and function of the microorganisms that inhabit an environment (eg. body sites/clinical samples). The interactions between these microorganisms and our bodies cells are important for both health and pathology.
From the research undertaken by the Trust we understand that ONT is the sole provider of long-read nanopore sequencing, in particular:
- ONT Promethion is able to deliver >30M long-read RNA and DNA sequences from any metagenomic sample from a single flow cell. The sequences are routinely >3Kb in length. The ONT technology is able to uniquely deliver sub-species level characterisation of community composition.
- ONT Promethion includes real-time adaptive sequencing capabilities. This means that samples can be enriched for specific sequences during the data generation which is essential to overcome host contamination in clinical metagenomics samples.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Oxford Nanopore Technologies | £398,001 † | — | Awarded |
Contracts
Contract 000859-2023-HUTH/23/003-1 · Oxford Nanopore Technologies
- Signed
- 11 Jan 2023
- Value
- £398,001
- Status
- active
Contracting authority & participating public bodies
Bidders & participating suppliers
1 commercial party on the notice- Oxford Nanopore TechnologiesAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.